Steven Cohen's Point72 Asset Management just pulled off what most fund managers only dream of — doubling the S&P 500's three-year return — and he's still not easing up. The billionaire investor's next move? A fresh swing into biotech, backing Palisade Bio Inc (NASDAQ:PALI) — a tiny, high-volatility stock working on gut-health therapies that's suddenly caught Wall Street's attention.Track PALI stock here.A Hedge Fund That Hits For PowerThe top 20 holdings in Point72's Q2 filing have surged 131% cumulatively ...

Novo Nordisk ( NVO ) stock has had quite a few ups and downs since Liberation Day, and we haven't quite seen the same recovery as other biopharma stocks since. Year to date, the S&P and EliI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges b ...

Group 1 - The article highlights the success of a buy call on Intellia Therapeutics, Inc. (NASDAQ: NTLA) made on August 15, which has resulted in a significant increase in the stock's value [1] - The investing group Haggerston BioHealth offers insights for both novice and experienced biotech investors, including catalysts to monitor and buy/sell ratings [1] - The group provides comprehensive financial analyses, including product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-by-market analysis for major pharmaceutical companies [1] Group 2 - The author, Edmund Ingham, has over five years of experience in covering biotech, healthcare, and pharma sectors, having prepared detailed reports on more than 1,000 companies [1]

Group 1 - The Federal Reserve is expected to announce a 25 basis points reduction in the Fed Funds rate at the upcoming FOMC meeting [1] - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates [2] - The investing group provides market commentary and portfolio updates every weekend, enhancing investor engagement and information sharing [2] Group 2 - The article emphasizes the importance of covered call trades in the biotech sector, indicating a focus on specific trading strategies [1] - There is a growing interest in biotech stocks, as indicated by the discussions within The Biotech Forum [2] - The article does not disclose any positions in the mentioned companies, ensuring an unbiased perspective [3]

Group 1 - Novo Nordisk announced job cuts and reduced profit guidance for 2025, which is surprising given the potential of its leading drug, semaglutide [1] - The article emphasizes the importance of staying updated on stocks in the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including sales forecasts and financial analyses for major pharmaceutical companies [1] Group 2 - The article is authored by a biotech consultant with over five years of experience in the industry, who has prepared detailed reports on more than 1,000 companies [1]

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, aimed at both novice and experienced investors [1] - The newsletter provides insights on key trends, catalysts driving valuations, product sales forecasts, and integrated financial statements for major pharmaceutical companies [1] - The author, Edmund Ingham, has over 5 years of experience in covering biotech, healthcare, and pharma, and has prepared detailed reports on more than 1,000 companies [1]

Group 1 - Viking Therapeutics' stock fell 42% on August 19, 2025, due to disappointing Phase 2 results for its oral obesity pill VK2735, which showed only up to 12.2% weight loss over three months, underperforming compared to competitors like Eli Lilly and Novo Nordisk [2] - 28% of patients discontinued VK2735 therapy due to side effects such as nausea and vomiting, indicating potential challenges in patient adherence [2] - Despite the setback with VK2735, Viking has a diversified pipeline with several promising candidates that may be undervalued by the market [3] Group 2 - Viking's current stock price of $24 is significantly below the analyst average price target of $89, suggesting a valuation disconnect that may not be justified given the company's diversified pipeline [3] - The Phase 3 trials for VK2735's subcutaneous formulation began in June 2025, and prior Phase 2 data indicated a viable injectable route with up to 13.1% placebo-adjusted weight loss [6] - Other pipeline assets include VK2809 for NASH/MASH, VK5211 for hip fracture recovery, VK0612 for type 2 diabetes, and VK0214 for X-linked adrenoleukodystrophy, contributing to further diversification [6] Group 3 - Key risks for Viking include potential clinical disappointments, substantial capital needs for Phase 3 trials, and intense competition in metabolic disorders [7] - For risk-tolerant long-term investors, the current valuation may over-penalize the company for the shortcomings of one program, presenting a speculative investment opportunity [7] - The conclusion suggests that if execution improves across other programs, the diversified pipeline could offer meaningful long-term upside [7]

Core Insights - The article emphasizes the importance of understanding the science behind biotech investments to avoid pitfalls in the industry [1]. Group 1 - The author has a PhD in biochemistry and extensive experience analyzing clinical trials and biotech companies [1]. - The mission is to educate investors on the scientific aspects of biotech businesses to facilitate informed decision-making [1].

Core Insights - The article emphasizes the importance of understanding the science behind biotech investments to avoid pitfalls in the industry [1] Group 1 - The author has a PhD in biochemistry and extensive experience analyzing clinical trials and biotech companies [1] - The mission is to educate investors on the scientific aspects of biotech businesses [1]

Group 1 - The article discusses the importance of staying updated on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - It mentions the investment group Haggerston BioHealth, which provides insights for both novice and experienced biotech investors, including buy and sell ratings, product sales forecasts, and financial analyses [1] - The author, Edmund Ingham, has extensive experience in the biotech sector, having covered over 1,000 companies and leading the Haggerston BioHealth investing group [1]